OncoMatch/Clinical Trials/NCT05934513
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Is NCT05934513 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GFH009 for relapsed or refractory peripheral t-cell lymphoma (ptcl).
Treatment: GFH009 — This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: within 2 weeks prior to starting study drug
Patients who have received chemotherapy, radiotherapy or anti-tumor Chinese traditional medicines within 2 weeks prior to starting study drug
Cannot have received: radiotherapy
Exception: within 2 weeks prior to starting study drug
Patients who have received chemotherapy, radiotherapy or anti-tumor Chinese traditional medicines within 2 weeks prior to starting study drug
Cannot have received: anti-tumor Chinese traditional medicines
Exception: within 2 weeks prior to starting study drug
Patients who have received chemotherapy, radiotherapy or anti-tumor Chinese traditional medicines within 2 weeks prior to starting study drug
Cannot have received: targeted therapy
Exception: within 4 weeks or 5 half-lives whichever is shorter
received targeted therapy within 4 weeks or 5 half-lives whichever is shorter
Cannot have received: immunotherapy
received immunotherapy
Cannot have received: autologous hematopoietic cell transplant
Exception: within 90 days before screening
History of autologous HCT within 90 days before screening
Cannot have received: allogeneic stem cell transplant
Exception: within 90 days before screening
History of allogeneic stem cell transplant within 90 days before screening
Cannot have received: CDK9 inhibitor
History of previous exposure to any other CDK9 inhibitor
Lab requirements
Blood counts
Adequate haematologic function at screening
Kidney function
Adequate organ function at screening
Liver function
Adequate organ function at screening
Adequate haematologic and organ function at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify